|
[Related PubMed/MEDLINE]
Total Number of Papers: 37
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: CDO1 |
| Long Form |
: cysteine dioxygenase 1 |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
A BIRC5High COD1Low Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients. |
BIRC5, OS, RFS, TNBC |
| 2 |
2022 |
Hypermethylated CDO1 and ZNF454 in Cytological Specimens as Screening Biomarkers for Endometrial Cancer. |
AH, AUC, EC, qMSP, Se, Sp, ZNF454 |
| 3 |
2022 |
Predictive Significance of Promoter DNA Methylation of Cysteine Dioxygenase Type 1 (CDO1) in Metachronous Gastric Cancer. |
EGC, ESD, MGC, TAM |
| 4 |
2021 |
Endogenous Taurine Downregulation Is Required for Renal Injury in Salt-Sensitive Hypertensive Rats via CBS/H2S Inhibition. |
CBS, CSAD, RAAS, SBP, SOD1, SOD2 |
| 5 |
2021 |
Prospective study to validate the clinical utility of DNA diagnosis of peritoneal fluid cytology test in gastric cancer. |
CEA, CY, GC, pT |
| 6 |
2020 |
Analysis of the methylation of CpG islands in the CDO1, TAC1 and CHFR genes in pancreatic ductal cancer. |
CHFR, TAC1 |
| 7 |
2020 |
Metabolism of Sulfur-Containing Amino Acids: How the Body Copes with Excess Methionine, Cysteine, and Sulfide. |
CBS, Cys, GNMT, Hcy, MAT, Met, SAM |
| 8 |
2020 |
Molecular analysis of the human placental cysteine dioxygenase type 1 gene. |
--- |
| 9 |
2020 |
Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN). |
HGD, IC, IPMN, qMSP |
| 10 |
2020 |
Promoter hypermethylation of cysteine dioxygenase type 1 in patients with non-small cell lung cancer. |
cMSP, MOB-qMSP, NSCLC |
| 11 |
2019 |
Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer. |
p-stage |
| 12 |
2019 |
Clinical significance of cancer specific methylation of the CDO1 gene in small bowel cancer. |
CRC, SBC |
| 13 |
2019 |
Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer. |
CSA, NSCLC |
| 14 |
2019 |
Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer. |
AUC, EUS-FNA, MV, PDAC |
| 15 |
2019 |
Differential Prognostic Relevance of Promoter DNA Methylation of CDO1 and HOPX in Primary Breast Cancer. |
BC, HOPX |
| 16 |
2018 |
Cysteine dioxygenase type 1 (CDO1) gene promoter methylation during the adenoma-carcinoma sequence in colorectal cancer. |
ACS, CRC, NAM |
| 17 |
2018 |
Epigenetic Status of CDO1 Gene May Reflect Chemosensitivity in Colon Cancer with Postoperative Adjuvant Chemotherapy. |
CRC, MMP, PCR |
| 18 |
2018 |
HNF4alpha Regulates CSAD to Couple Hepatic Taurine Production to Bile Acid Synthesis in Mice. |
ASBT, CSAD, FXR, HNF4alpha, SHP |
| 19 |
2018 |
Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma. |
AC, BTC, EHCC, OS |
| 20 |
2017 |
Cysteine Dioxygenase 1 Mediates Erastin-Induced Ferroptosis in Human Gastric Cancer Cells. |
GC, GPX4, ROS |
| 21 |
2017 |
Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease. |
GBC, qMSP |
| 22 |
2017 |
Promoter methylation of cysteine dioxygenase type 1: gene silencing and tumorigenesis in hepatocellular carcinoma. |
HCC |
| 23 |
2017 |
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. |
BEA |
| 24 |
2016 |
CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. |
BCR, PCa |
| 25 |
2016 |
Cysteine Dioxygenase Type 1 Inhibits Osteogenesis by Regulating Wnt Signaling in Primary Mouse Bone Marrow Stromal Cells. |
ALP, BMSCs, MSCs |
| 26 |
2016 |
Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer. |
BC, qMSP |
| 27 |
2015 |
Cysteine dioxygenase type 1 promotes adipogenesis via interaction with peroxisome proliferator-activated receptor gamma. |
mBMSCs |
| 28 |
2015 |
Epigenetic regulation of the novel tumor suppressor cysteine dioxygenase 1 in esophageal squamous cell carcinoma. |
ESCC |
| 29 |
2015 |
Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome. |
ccRCC, CI, NLCS |
| 30 |
2014 |
Detection of methylated CDO1 in plasma of colorectal cancer; a PCR study. |
CRC |
| 31 |
2014 |
Differential expression of cysteine dioxygenase 1 in complex karyotype liposarcomas. |
DDLSs, hMSCs, IHC, WDLSs |
| 32 |
2014 |
Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. |
CHB, HBV, HCC, LC, MSP |
| 33 |
2013 |
Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth. |
CSA |
| 34 |
2013 |
Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines. |
ROS |
| 35 |
2012 |
Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers. |
CRC |
| 36 |
2011 |
The synthesis and role of taurine in the Japanese eel testis. |
CSD, DHP |
| 37 |
2010 |
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients. |
LNP |
|
A Search Service for Abbreviation / Long Form
